Amyotrophic lateral sclerosis (ALS), a heterogeneous syndrome recognised clinically as a
progressive degeneration of the upper and lower motor neurons, is traditionally classed as a …

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder characterized by upper
motor neuron, corticospinal tract, and lower motor neuron involvement. In 1874, Jean-Martin …

Objective: To assess the effect of eligibility criteria in amyotrophic lateral sclerosis (ALS)
clinical trials on the representativeness of the enrolled population. Methods: Patients …

The development of the disease modifying drug, riluzole, is changing the natural history of
amyotrophic lateral sclerosis (ALS). Let us take the 'classic'ALS patient as portrayed by ALS …

Parkinson's disease is “in the spotlight”, and with very good reason, enthuses Thomas
Chase (US National Institutes of Neurological Disorders and Stroke, Bethesda, MD …

When it comes to announcing an effective treatment for a currently untreatable disease,
investigators have a grave responsibility. Bensimon et al. 1 report in this issue of the Journal …

Neurologists told Neurology Today that they would most likely offer a newly approved drug
for amyotrophic lateral sclerosis to their patients, but they would be honest in suggesting that …

Amyotrophic lateral sclerosis (ALS) is an idiopathic, fatal neurodegenerative disease of the
human motor system. In this Seminar, we summarise current concepts about the origin of the …

Reports that the US Food and Drug Administration's Peripheral and Central Nervus System
Drugs Advisory Committee has agreed to recommend the approval of Rhone-Poulenc …

Riluzole is the only therapy proven in clinical trials to prolong amyotrophic lateral sclerosis
(ALS) survival (approximately three months). Questions remain concerning riluzole's …